[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100106337":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":11,"locations":32,"responsibleParty":61,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":11,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":85,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","ACTIVE_COMPARATOR",null,[13],"Drug: valdecoxib",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2",[17],"Drug: naproxen",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","valdecoxib","valdecoxib 10 mg tablet by mouth once daily for 6 weeks",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"naproxen","naproxen 500 mg capsule by mouth twice daily for 6 weeks",[15],[29],{"name":30,"affiliation":5,"role":31},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[33,39,47,54],{"facility":34,"status":11,"city":35,"state":36,"zip":11,"country":37,"countryCode":38,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Pfizer Investigational Site","Kweishan","Taoyuan","Taiwan","TW",{"facility":34,"status":11,"city":40,"state":11,"zip":11,"country":37,"countryCode":38,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Kaohsiung City",{"type":42,"coordinates":43},"Point",[44,45],120.31333,22.61626,{"lat":45,"lon":44},{"facility":34,"status":11,"city":48,"state":11,"zip":11,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":11},"Taichung",{"type":42,"coordinates":50},[51,52],120.6839,24.1469,{"lat":52,"lon":51},{"facility":34,"status":11,"city":55,"state":11,"zip":11,"country":37,"countryCode":38,"cosmosGeoPoint":56,"geoPoint":60,"contacts":11},"Taipei",{"type":42,"coordinates":57},[58,59],121.52639,25.05306,{"lat":59,"lon":58},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":62,"oldOrganization":63},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100106337","phase-3-a-double-blind-double-dummy-randomized-comparison-study-of-the-efficacy-and-safety-of-valdecoxib-10mg-once-daily-and-naproxen-500mg-twice-daily-in-treating-the-signs-and-symptoms-of-osteoarthritis-of-the-knee-or-hip-in-taiwan-100106337",false,"NCT00648258","A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan","A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg QD And Naproxen 500mg BID In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan","Inclusion Criteria:\n\n* The diagnosis of hip OA, which was having hip pain and meeting criteria for at least 2 of the following: a. Westergren erythrocyte sedimentation rate of \\\u003C 20 mm\u002Fhr; b. radiographic femoral or acetabular osteophytes or c. radiographic joint space narrowing\n* Knee OA diagnosis required diagnosing (by modified American College of Rheumatology criteria) OA of the knee with pain plus at least one of the following: a. Age\\> 50 years old, b. Stiffness \\\u003C 30 minutes, c. crepitus on active motion and radiographic evidence of OA of the knee, defined as presence of osteophytes or joint space narrowing\n* Symptomatic OA of the knee or hip was determined at the Baseline Visit, if the Patient's Assessment of Arthritis Pain was at least 40 mm VAS, Patient's and the Physician's Global Assessment of Arthritis was \"poor\" or \"very poor\"\n\nExclusion Criteria:\n\n* Use of NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) before baseline arthritis assessments","ALL","18 Years",{"count":74,"type":75},130,"ACTUAL","INTERVENTIONAL",[78],"PHASE3","To evaluate the efficacy, safety, and tolerability of valdecoxib by comparing valdecoxib 10 mg daily (QD) with naproxen 500 mg twice daily (BID) in treating the signs and symptoms of osteoarthritis (OA) of the knee or hip. The study was designed to collect comparative information for the local population (Taiwan).",[81],"Osteoarthritis",[83,84],"osteoarthritis, knee","osteoarthritis, hip","COMPLETED","2018-12-03",{"date":88,"type":75},"2018-12-05",{"date":90,"type":11},"2003-07",{"date":92,"type":75},"2004-04",{"name":5,"class":6},4]